A61K 31/4741
Condensed with ring systems having oxygen as a ring hetero atom
Official title: condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K31/4741 (Condensed with ring systems having oxygen as a ring hetero atom) appears on 291 US grants and 486 published applications in this corpus.
Search patents in A61K- Granted patents
- 291
- Published applications
- 486
- Assignees
- 300
- Inventors
- 1,121
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 8 | 0 |
| 1998 | 6 | 0 |
| 1999 | 5 | 0 |
| 2000 | 8 | 0 |
| 2001 | 13 | 3 |
| 2002 | 7 | 8 |
| 2003 | 9 | 12 |
| 2004 | 4 | 17 |
| 2005 | 8 | 12 |
| 2006 | 1 | 18 |
| 2007 | 2 | 13 |
| 2008 | 1 | 7 |
| 2009 | 3 | 15 |
| 2010 | 6 | 20 |
| 2011 | 5 | 11 |
| 2012 | 10 | 12 |
| 2013 | 10 | 29 |
| 2014 | 18 | 24 |
| 2015 | 16 | 33 |
| 2016 | 27 | 36 |
| 2017 | 23 | 13 |
| 2018 | 14 | 25 |
| 2019 | 15 | 24 |
| 2020 | 14 | 17 |
| 2021 | 8 | 22 |
| 2022 | 10 | 19 |
| 2023 | 9 | 23 |
| 2024 | 10 | 27 |
| 2025 | 14 | 22 |
| 2026 | 4 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Therapy for drug-resistant cancer by administration of anti-HER2 antibody/drug conjugate4 Aug 2026US 12,698,342 B2Daiichi Sankyo Company, Limited
- Method for inhibiting infection of SARS-CoV-2 in a subject14 Jul 2026US 12,678,471 B2Chang Gung University of Science and Technology
- Formulation14 Apr 2026US 12,599,555 B2Hewlett Healthcare Ltd
- KRAS inhibitors14 Apr 2026US 12,600,733 B2Eli Lilly and Company
- Nitrogen-containing heterocyclic compound and use thereof23 Dec 2025US 12,502,386 B2Shanghai Shijiang Biotechnology Co., Ltd
- Inhaled statins as bronchodilators to improve lung function in respiratory diseases8 Oct 2026US 2026/0306477 A1Beth Israel Deaconess Medical Center, Inc.
- Novel ras inhibitors1 Oct 2026US 2026/0294893 A1
- Treatment of non-small cell lung cancer with a combination of 3-amino-3-(1-methyl-1h-imidazol-5-yl)-6-oxa-2(4,6)-quinolina-1,4(1,3)-dibenzenacyclohexaphane-22,44-dicarbonitrile and an egfr-tki24 Sep 2026US 2026/0284034 A1
- Use of retinoic acid receptor activator and composition thereof in regeneration and repair of mammals17 Sep 2026US 2026/0272871 A1Beijing Institute for Stem Cell and Regenerative Medicine
- Episynchrons for precision medicine10 Sep 2026US 2026/0265341 A1
Most cited
By later US patents
- Aerosol formulations containing propellant 134a and fluticasone propionate159US 5,658,549 AGlaxo Group Limited · 1997
- Naphtholactams and lactones as bone morphogenetic protein active agents119US 6,030,967 ATakeda Chemical Industries, Ltd. · 2000
- Canisters containing aerosol formulations containing P134a and fluticasone propionate107US 5,674,472 AGlaxo Group Limited · 1997
- Canister containing aerosol formulations containing P134a and particulate medicaments92US 5,683,676 AGlaxo Group Limited · 1997
- Aerosol formulations containing P134a and salbutamol84US 5,674,471 AGlaxo Group Limited · 1997